{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:43:47Z","timestamp":1781829827927,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The baseline treatment of differentiated thyroid cancer (DTC) consists of thyroidectomy followed by postoperative risk-adapted radioiodine therapy (RAIT) when indicated. The choice of most appropriate RAI activities to administer with the aim to reach an efficient remnant ablation and reduce the risk of recurrence is yet an open issue and the detection of basal factors that may predict treatment response seems fundamental. The aim of this study was to investigate the potential role of Hashimoto thyroiditis (HT) in predicting 1-year and 5-year treatment response after RAIT and prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively included 314 consecutive patients (174 low-risk and 140 intermediate-risk) who received thyroidectomy plus RAIT. One-year and 5-year disease status was evaluated according to 2015 ATA categories response based upon biochemical and structural findings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HT was reported histopathologically in 120 patients (38%). DTC patients with concomitant HT received a higher number of RAITs and cumulative RAI activities. Initial RAIT reached an excellent response in 63% after one year and 84% after 5\u00a0years. The rate of excellent response one year and 5-year after first RAIT was significantly lower in HT groups, compared to not HT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Instead, HT did not have a prognostic role considering PFS and OS; while stimulate thyroglobulin (sTg) at ablation was significantly related to survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>HT may affect the efficacy of RAIT in low to intermediate risk DTC, particularly reducing the successful rate of excellent response after RAIT. Instead, HT did not have a prognostic impact such as stimulated sTg.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-021-01644-1","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T10:03:41Z","timestamp":1624269821000},"page":"1089-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatrice","family":"Panarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Galani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Casella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","volume":"361","author":"SI Sherman","year":"2003","unstructured":"Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501\u201311.","journal-title":"Lancet"},{"key":"1644_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133.","journal-title":"Thyroid"},{"key":"1644_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1530\/EJE-18-0253","volume":"179","author":"D Albano","year":"2018","unstructured":"Albano D, Bertagna F, Bonacina M, Durmo R, Cerudelli E, Gazzilli M, et al. Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. Eur J Endo. 2018;179:143\u201351.","journal-title":"Eur J Endo"},{"key":"1644_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12020-018-1713-2","volume":"63","author":"D Albano","year":"2019","unstructured":"Albano D, Panarotto MB, Durmo R, Rodella C, Bertagna F, Giubbini R. Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer. Endocrine. 2019;63:79\u201386.","journal-title":"Endocrine"},{"issue":"4","key":"1644_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"RM Tuttle","year":"2019","unstructured":"Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourget P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid Cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29(4):461\u201370.","journal-title":"Thyroid"},{"key":"1644_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1089\/thy.2010.0308","volume":"20","author":"J Jonklaas","year":"2010","unstructured":"Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010;20:1423\u20134.","journal-title":"Thyroid"},{"key":"1644_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S2213-8587(18)30207-9","volume":"6","author":"E Hindie","year":"2018","unstructured":"Hindie E, Taieb D, Avram AM, Giovanella L. Radioactive iodine ablation in low-risk thyroid cancer. Lancet Diabetes Endocrinol. 2018;6:686.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1644_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.suronc.2019.05.011","volume":"29","author":"AS Moten","year":"2019","unstructured":"Moten AS, Zhao H, Willis AI. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients. Surg Oncol. 2019;29:184\u20139.","journal-title":"Surg Oncol"},{"key":"1644_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s12020-019-02148-9","volume":"68","author":"D Albano","year":"2020","unstructured":"Albano D, Bonacina M, Durmo R, Bertagna F, Giubbini R. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low risk differentiate thyroid cancer. Endocrine. 2020;68:124\u201331.","journal-title":"Endocrine"},{"key":"1644_CR10","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","volume":"366","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663\u201373.","journal-title":"N Engl J Med"},{"key":"1644_CR11","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMoa1109589","volume":"366","author":"U Mallick","year":"2012","unstructured":"Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674\u201385.","journal-title":"N Engl J Med"},{"key":"1644_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ans.12368","volume":"85","author":"JB Bai","year":"2013","unstructured":"Bai JB, Shakerian R, Westcott JD, Lichtenstein M, Miller JA. Factors influencing radioiodine uptake after thyroid cancer surgery. ANZ J Surg. 2013;85:572\u20137.","journal-title":"ANZ J Surg"},{"key":"1644_CR13","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1007\/s00259-005-1866-0","volume":"32","author":"MO Bernier","year":"2005","unstructured":"Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, et al. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2005;32:1418\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1644_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/jc.2006-1345","volume":"92","author":"A Hackshaw","year":"2007","unstructured":"Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92:28\u201338.","journal-title":"J Clin Endocrinol Metab"},{"key":"1644_CR15","doi-asserted-by":"publisher","first-page":"E730","DOI":"10.1002\/hed.24080","volume":"38","author":"H Kwon","year":"2015","unstructured":"Kwon H, Choi JY, Moon JH, Park HJ, Lee WW, Lee KE. Effect of Hashimoto thyroiditis on low-dose radioactive-iodine remnant ablation. Head Neck. 2015;38:E730\u20135.","journal-title":"Head Neck"},{"key":"1644_CR16","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s12020-019-01935-8","volume":"66","author":"P Del Rio","year":"2019","unstructured":"Del Rio P, Montana C, Cozzani F, Rossini M, Loderer T, Dall\u2019Aglio E, et al. Is there a correlation between thyroiditis and thyroid cancer? Endocrine. 2019;66:538\u201341.","journal-title":"Endocrine"},{"key":"1644_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00432-014-1629-z","volume":"140","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Dai J, Wu T, Yang N, Yin Z. The study of the coexistence of Hashimoto\u2019s thyroiditis with papillary thyroid carinoma. J Cancer Res Clin Oncol. 2014;140:1021\u20136.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1644_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12902-019-0351-x","volume":"19","author":"G Graceffa","year":"2019","unstructured":"Graceffa G, Patrone R, Vieni S, Campanella S, Calamia S, Laise I, et al. Association between Hashimoto\u2019s thyroiditis and papillary thyroid carcinoma: a retrospective analysis of 305 patients. BMC Endocr Disord. 2019;19:26.","journal-title":"BMC Endocr Disord"},{"key":"1644_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1055\/a-0648-4593","volume":"50","author":"Y Nagayama","year":"2018","unstructured":"Nagayama Y. Thyroid autoimmunity and thyroid cancer-the pathogenic conenction: a 2018 update. Horm Metab Res. 2018;50:922\u201331.","journal-title":"Horm Metab Res"},{"key":"1644_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/CCO.0000000000000150","volume":"27","author":"SI Noureldine","year":"2015","unstructured":"Noureldine SI, Tufano RP. Assoication of Hashimoro\u2019s thyroiditis and thyroid cancer. Curr Opin Oncol. 2015;27:21\u20135.","journal-title":"Curr Opin Oncol"},{"key":"1644_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40618-017-0794-8","volume":"41","author":"T Pilli","year":"2018","unstructured":"Pilli T, Toti R, Occhini R, Cantara S, Caselli M, Cardinale S, et al. Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes. J Endocrinol Invest. 2018;41:703\u20139.","journal-title":"J Endocrinol Invest"},{"key":"1644_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/ERC-17-0085","volume":"24","author":"V Marotta","year":"2017","unstructured":"Marotta V, Sciammarella C, Chiofalo MG, Gambardella C, Bellevicine C, Grasso M, et al. Hashimoto\u2019s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer. 2017;24:485\u201393.","journal-title":"Endocr Relat Cancer"},{"key":"1644_CR23","volume-title":"AJCC cancer staging manual","author":"M Tuttle","year":"2017","unstructured":"Tuttle M, Morris LF, Haugen B, Shah J, Sosa JA, Rohren E, Subramaniam RM, Hunt JL, Perrier ND. Thyroid-differentiated and anaplastic carcinoma (Chapter 73). In: Amin MB, Edge SB, Greene F, Byrd D, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley J, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing; 2017.","edition":"8"},{"key":"1644_CR24","doi-asserted-by":"publisher","first-page":"101367","DOI":"10.1016\/j.beem.2019.101367","volume":"33","author":"F Ragusa","year":"2019","unstructured":"Ragusa F, Fallahi P, Elia G, Gonnella D, Paparo SR, Giusti C, et al. Hashimto\u2019s thyroiditis: epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metabol. 2019;33:101367.","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"1644_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/00000478-200005000-00001","volume":"24","author":"GA Derringer","year":"2000","unstructured":"Derringer GA, Thompson LD, Frommelt RA, Bijwaard KE, Heffess CS, Abbondanzo SL. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol. 2000;24:623\u201339.","journal-title":"Am J Surg Pathol"},{"key":"1644_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1089\/thy.1999.9.1273","volume":"9","author":"P Kossev","year":"1999","unstructured":"Kossev P, Livolsi V. Lymphoid lesions of the thyroid: review in light of the revised European-American lymphoma classification and upcoming World Health Organization classification. Thyroid. 1999;9:1273\u201380.","journal-title":"Thyroid"},{"key":"1644_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/archsurg.1955.01270080137023","volume":"70","author":"ME Dailey","year":"1955","unstructured":"Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955;70:291\u20137.","journal-title":"AMA Arch Surg"},{"key":"1644_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/EJE-12-0903","volume":"168","author":"JH Lee","year":"2013","unstructured":"Lee JH, Kim Y, Choi JW, Kim YS. The association between papillary thyroid carcinoma and histologically proven Hashimoto\u2019s thyroiditis: a meta-analysis. Eur J Endocrinol. 2013;168:343\u20139.","journal-title":"Eur J Endocrinol"},{"key":"1644_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1210\/jc.2012-2978","volume":"98","author":"B Jankovic","year":"2013","unstructured":"Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto\u2019s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab. 2013;98:474\u201382.","journal-title":"J Clin Endocrinol Metab"},{"key":"1644_CR30","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1210\/jc.2012-1083","volume":"97","author":"DS McLeod","year":"2012","unstructured":"McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab. 2012;97:2682\u201392.","journal-title":"J Clin Endocrinol Metab"},{"key":"1644_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12149-014-0854-5","volume":"28","author":"N Yildirim-Poyraz","year":"2014","unstructured":"Yildirim-Poyraz N, Yazgan A, Ozdemir E, Gozalan A, Keskin M, Ersoy R, et al. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients. Ann Nucl Med. 2014;28:623\u201331.","journal-title":"Ann Nucl Med"},{"key":"1644_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1089\/thy.2011.0311","volume":"22","author":"I Kollecker","year":"2012","unstructured":"Kollecker I, von Wasielewski R, Langner C, Muller JA, Spitzweg C, Kreipe H, et al. Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues. Thyroid. 2012;22:529\u201335.","journal-title":"Thyroid"},{"key":"1644_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/MNM.0b013e328345f8be","volume":"32","author":"SM Wagieh","year":"2011","unstructured":"Wagieh SM, El-Refaei SM, Salem SS, Al-Shiekh EA, Al-Ghamdy HA, Al-Juhani NR. Impact of histopathology of non-neoplastic thyroid tissue on ablation outcome in patients with papillary thyroid cancer. Nucl Med Commun. 2011;32:597\u2013604.","journal-title":"Nucl Med Commun"},{"key":"1644_CR34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341\u20139.","journal-title":"Thyroid"},{"key":"1644_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1365-2265.2012.04342.x","volume":"77","author":"F Vaisman","year":"2012","unstructured":"Vaisman F, Momesso D, Bulzico DA, Pessoa CHCN, Dias F, Corbo R, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf). 2012;77:132\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1644_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1210\/jcem.84.2.5443","volume":"84","author":"KH Loh","year":"1999","unstructured":"Loh KH, Greenspan FS, Dong F, Miller TR, Yeo PP. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocr Metabolism. 1999;84:458\u201363.","journal-title":"J Clin Endocr Metabolism"},{"key":"1644_CR37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3346\/jkms.2012.27.8.883","volume":"27","author":"JS Jeong","year":"2012","unstructured":"Jeong JS, Kim HK, Lee CR, Park S, Park JH, Kang SW, et al. Coexistence of chronic lymphocytic thyroiditis with papillary thyroid carcinoma: clinical manifestation and prognostic outcome. J Korean Med Sci. 2012;27:883\u20139.","journal-title":"J Korean Med Sci"},{"key":"1644_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF02984614","volume":"19","author":"PW Rosario","year":"2005","unstructured":"Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Reis JS, et al. Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer. Ann Nucl Med. 2005;19:247\u201350.","journal-title":"Ann Nucl Med"},{"key":"1644_CR39","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s10147-016-0956-2","volume":"21","author":"YW Chang","year":"2016","unstructured":"Chang YW, Kim HS, Jung SP, Kim HY, Lee JB, Bae JW, et al. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. Int J Clin Oncol. 2016;21:862\u20138.","journal-title":"Int J Clin Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01644-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01644-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T18:22:00Z","timestamp":1630434120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01644-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01644-1","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"17 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}